StockNews.AI
QURE
StockNews.AI
1 min

QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

1. Kessler Topaz investigates potential securities law violations for uniQure investors. 2. uniQure's FDA communication impacted AMT-130's BLA submission timeline negatively. 3. Stock price dropped over 50% after FDA's feedback regarding AMT-130 data. 4. uniQure’s previous stock price was $67.69 before falling to $34.29.

4m saved
Insight
Article

FAQ

Why Very Bearish?

UniQure's stock lost over half its value due to FDA concerns about AMT-130, mirroring past impacts seen with similar biotech failures—such as Aegerion Pharmaceuticals post-FDA rejection, which faced dwindling investor confidence.

How important is it?

The serious implications from FDA's feedback and significant stock price drop mark high relevance, prompting investor scrutiny and concern over uniQure's future.

Why Short Term?

The immediate negative sentiment from the FDA news will likely persist short-term, based on historical trends in biotech responses to adverse regulatory feedback.

Related Companies

AUPHCBAYSGMO
, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) ("uniQure"). On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission.  Specifically, uniQure disclosed that the company believes the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate to provide the primary evidence in support of a BLA submission, and that the timing of the BLA submission for AMT-130 is now unclear as a result.   On this news, the price of uniQure's stock fell over 50%, from a close of $67.69 on October 31, 2025, to close at $34.29 on November 3, 2025. If you are a uniQure investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or E-mail at [email protected]. You can also click on the following link or paste it in your browser:   https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&mktm=PR Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.  The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).  For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.   CONTACT: Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.280 King of Prussia RoadRadnor, PA 19087(484) 270-1453[email protected] May be considered attorney advertising in certain jurisdictions.  Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP

Related News